Call for Your FREE Evaluation (877) 503-1595

PRADAXA VS. WARFARIN: BETTER OR JUST MORE COSTLY?

Areas of Practice

Get a FREE Evaluation

By submitting this form you agree to be contacted by KirkendallDwyer.com affiliates and/or attorneys regarding your claim. You consent to KirkendallDwyer.com contacting you through the use of text message, phone call, and electronic mail message even if your number is a wireless number or if I am presently listed on a Do Not Call list. My consent does not require purchase.

Call for your FREE consultation with a personal attorney: (877) 503-1595

Pradaxa

PRADAXA VS. WARFARIN: BETTER OR JUST MORE COSTLY?

Is Pradaxa, the first alternative to the original blood thinner warfarin, worth its $3000 a year price tag, or is it just as risky as the $200 a year warfarin?  The number of Pradaxa injuries leading to lawsuits would indicate that the new drug isn’t a step forward for patients at all. The FDA approved…..

Posted in Pharmaceutical and Medical Device News,
Tagged Blood Thinning Medication, Pradaxa,

JAMA STATES THAT FDA TOO QUICK TO APPROVE PRADAXA

Is the FDA’s push to approve drugs more quickly costing too much in the way of patient safety?  According to an article published in the Journal of the American Medical Association by two drug-safety experts, the answer is yes. They cite three drugs, including the controversial blood thinner Pradaxa, that were approved in an accelerated…..

Posted in Pharmaceutical and Medical Device News,
Tagged Blood Thinning Medication, Pradaxa, FDA, Caprelsa, Fingolimod, JAMA,

LATEST FROM THE FDA REGARDING PRADAXA

After Pradaxa gained the infamous distinction of being the most deadly drug of 2011, the FDA vowed to investigate its safety further.  On November 2, the FDA released a Drug Safety Communication explaining that the bleeding rates associated with Pradaxa use are not any higher than with warfarin use. Pradaxa is the first alternative to…..

Posted in Pharmaceutical and Medical Device News,
Tagged Pradaxa, FDA, warfarin,

FDA Rejects a New Use for Xarelto

Xarelto, an alternative to warfarin, the traditional treatment for atrial fibrillation, has suffered another rejection by the FDA. This is the second time that Johnson & Johnson has tried to get Xarelto approved to treat acute coronary syndrome, and the second time the FDA has refused to do so.

Posted in Pharmaceutical and Medical Device News,
Tagged Pradaxa, FDA, Drug Safety, Pradaxa Attorney, Warafin, Xarelto,